PFS in patients with high-risk cytogenetics in recent trials for relapsed multiple myeloma
| . | Median PFS . | ||
|---|---|---|---|
| Regimen . | All high risk . | Del(17p) . | t(4;14) . |
| KRd vs Rd19 | 23.1 vs 13.9 mo (HR = 0.70) | 24.5 vs 11.1 mo (HR = NA) | 23.1 vs 16.7 mo (HR = NA) |
| Kd vs Vd35 | 8.8 vs 6.0 mo (HR = 0.646) | 7.6 vs 4.9 mo (HR = NA) | 10.1 vs 6.8 mo (HR = NA) |
| Elotuzumab-Rd vs Rd17 | NA | 21.2 vs 14.9 mo (HR = 0.70) | 15.8 vs 5.5 mo (HR = 0.52) |
| IRD vs Rd37 | 21.4 vs 9.7 mo (HR = 0.543) | 21.4 vs 9.7 mo (HR = 0.596) | 18.5 vs 12 mo (HR = 0.645) |
| DRd vs Rd16 | NR vs 10.2 (HR = 0.44) | NA | NA |
| . | Median PFS . | ||
|---|---|---|---|
| Regimen . | All high risk . | Del(17p) . | t(4;14) . |
| KRd vs Rd19 | 23.1 vs 13.9 mo (HR = 0.70) | 24.5 vs 11.1 mo (HR = NA) | 23.1 vs 16.7 mo (HR = NA) |
| Kd vs Vd35 | 8.8 vs 6.0 mo (HR = 0.646) | 7.6 vs 4.9 mo (HR = NA) | 10.1 vs 6.8 mo (HR = NA) |
| Elotuzumab-Rd vs Rd17 | NA | 21.2 vs 14.9 mo (HR = 0.70) | 15.8 vs 5.5 mo (HR = 0.52) |
| IRD vs Rd37 | 21.4 vs 9.7 mo (HR = 0.543) | 21.4 vs 9.7 mo (HR = 0.596) | 18.5 vs 12 mo (HR = 0.645) |
| DRd vs Rd16 | NR vs 10.2 (HR = 0.44) | NA | NA |
DRd, daratamumab, lenalidomide, dexamethasone; IRD, ixazomib, lenalidomide, dexamethasone; Kd, carfilzomib, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; NA, not applicable.